For more than a decade, digital transformation has driven predictions about the decline of the pharmaceutical sales representative.

Across Europe, that prediction has not materialised.

The field force remains one of the most influential assets in the commercial model. What is changing is not its relevance, but its role. The sales rep of 2026 will look fundamentally different from the sales rep of 2016.

Why Sales Rep Value Is Increasing in European Pharma

As access to healthcare professionals becomes more limited, the value of each interaction increases.

Frequency is no longer the differentiator. Relevance and value are.

At the same time, expectations are rising. Healthcare professionals now expect seamless follow-up, flexible virtual engagement, and personalised, clinically relevant content. Delivering this experience requires coordination across multiple touchpoints.

In leading organisations, the sales rep is becoming the central figure responsible for connecting these interactions into a coherent journey.

The Shift to an Omnichannel Orchestrator Role

The modern sales rep is no longer focused purely on in-person detailing. The role is evolving into one that connects channels, insights, and stakeholders.

This includes coordinating digital and face-to-face engagement, bringing tailored evidence into conversations, and working closely with medical, marketing, and market access teams. Reps are also expected to use data and AI-driven insights to prioritise actions and identify the most valuable opportunities.

This shift reflects a broader move towards integrated, omnichannel commercial models and requires a new set of capabilities.

Why Sales Force Transformation Often Stalls

Despite clear strategic intent, many organisations struggle to evolve the field force.

The challenge is not awareness. It is execution.

Common barriers include:

• Incentive models still focused on activity volume rather than engagement quality
• Limited training in hybrid and digital engagement
• Resistance from experienced field teams
• Lack of clarity around evolving role definitions

Transforming the sales rep role requires structural and cultural change, not just new skills.

How Leading Pharma Companies Are Redefining the Field Force

Organisations that are making progress are taking a more deliberate approach to role design, capability building, and performance management.

Rather than applying a single global model, they define different role archetypes based on market needs. Some roles are focused on hybrid engagement, others on key accounts, digital channels, or specific therapy areas. This reflects the diversity of European healthcare systems.

They are also investing in AI-enabled training and coaching. Simulation tools and real-time feedback help reps build confidence in areas such as remote engagement and objection handling.

At the same time, incentive models are evolving. Performance is increasingly measured by the quality of engagement, the ability to coordinate across channels, and the impact on customer behaviour. When incentives change, behaviours follow.

The Future of the Pharma Field Force in Europe

Over the next 12 to 36 months, the role of the sales rep will continue to shift.

Reps will spend less time presenting and more time coordinating. They will deliver more personalised engagement, make greater use of data, and operate across increasingly complex stakeholder environments.

The role is becoming more strategic, not less relevant.

The sales rep is not being replaced by digital transformation. The role is being redefined. In Europe, the most successful organisations are positioning their field force as the orchestrator of both digital and human engagement. Those that fail to evolve risk losing relevance in an increasingly data-driven and omnichannel commercial landscape.